Merck advances first pneumococcal conjugate vaccine specifically designed for adults

28 November 2023

US pharma giant Merck & Co (NYSE: MRK) has announced results from STRIDE-3, a Phase III trial evaluating V116, the company’s investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults.

The trial evaluated the immunogenicity, tolerability and safety of V116 compared to Pfizer’s (NYSE: PFE) Prevnar 20/Apexxnar or PCV20 (pneumococcal 20-valent conjugate vaccine), in adults who had not previously received a pneumococcal vaccine.

"Strong evidence to support the immunogenicity of V116 compared to the standard of care"V116 demonstrated superior immunogenicity for 10 of 11 unique serotypes compared to PCV20 in adults of 50 years of age and older.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK